MD1018Z - Method for treating migraine attack in patients with episodic migraine - Google Patents
Method for treating migraine attack in patients with episodic migraine Download PDFInfo
- Publication number
- MD1018Z MD1018Z MDS20150138A MDS20150138A MD1018Z MD 1018 Z MD1018 Z MD 1018Z MD S20150138 A MDS20150138 A MD S20150138A MD S20150138 A MDS20150138 A MD S20150138A MD 1018 Z MD1018 Z MD 1018Z
- Authority
- MD
- Moldova
- Prior art keywords
- migraine
- patients
- attack
- episodic
- timolol
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 22
- 206010027599 migraine Diseases 0.000 title claims abstract description 22
- 230000001667 episodic effect Effects 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 9
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims abstract description 10
- 229960004605 timolol Drugs 0.000 claims abstract description 10
- 239000006196 drop Substances 0.000 claims abstract description 7
- 239000003889 eye drop Substances 0.000 claims abstract description 7
- 229940012356 eye drops Drugs 0.000 claims abstract description 7
- 229960004324 betaxolol Drugs 0.000 claims abstract description 4
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 abstract description 5
- 206010019233 Headaches Diseases 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 208000000060 Migraine with aura Diseases 0.000 description 2
- 206010039729 Scotoma Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010054956 Phonophobia Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010034962 Photopsia Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910000065 phosphene Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940084765 timolol ophthalmic solution Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la neurologie şi poate fi utilizată pentru tratamentul atacului migrenos la pacienţii cu migrenă episodică. The invention relates to medicine, in particular to neurology and can be used for the treatment of migraine attacks in patients with episodic migraine.
Este cunoscută metoda de tratament al pacienţilor cu migrenă cronică prin administrarea picăturilor oftalmice de 0,5% de timolol, câte o picătură de 2 ori pe zi (în ochiul ipsilateral durerii), cu administrare permanentă [1]. The method of treating patients with chronic migraine is known by administering 0.5% timolol eye drops, one drop twice a day (in the eye ipsilateral to the pain), with permanent administration [1].
Dezavantajul acestei metode constă în administrarea permanentă a medicamentului, chiar în absenţa cefaleei, ceea ce nu este comod pentru pacienţi. Administrarea sistematică a medicamentului creşte probabilitatea de manifestare a efectelor sale adverse. The disadvantage of this method is that the drug must be taken continuously, even in the absence of a headache, which is inconvenient for patients. Systematic administration of the drug increases the likelihood of its adverse effects.
Sub formă de picături oftalmice timololul este folosit în tratamentul glaucomului. Timololul reduce producerea de umoare apoasă prin blocarea receptorilor beta-adrenergici din epiteliul corpului ciliar. Soluţia oftalmică de timolol se livrează sub formă de soluţie apoasă, izotonică, sterilă de 0,25% şi 0,5%, ce conţine 2,5 mg/ml şi 5 mg/ml respectiv. Timolol eye drops are used in the treatment of glaucoma. Timolol reduces the production of aqueous humor by blocking beta-adrenergic receptors in the ciliary body epithelium. Timolol ophthalmic solution is supplied as a sterile, isotonic, aqueous solution of 0.25% and 0.5%, containing 2.5 mg/ml and 5 mg/ml respectively.
Problema pe care o rezolvă invenţia dată constă în elaborarea unei metode eficiente, şi anume cu minimalizarea riscurilor de reacţii adverse la medicament la atacul migrenos la pacienţii cu migrenă episodică. The problem solved by this invention consists in developing an effective method, namely minimizing the risks of adverse drug reactions during migraine attacks in patients with episodic migraine.
Esenţa invenţiei constă în aceea că la apariţia primelor semne ale atacului migrenos se picură în ambii ochi picături oftalmice de 0,5% de timolol sau de 0,25% de betaxolol, câte o picătură de 1…3 ori, peste fiecare 15 min. The essence of the invention is that at the first signs of a migraine attack, 0.5% timolol or 0.25% betaxolol eye drops are instilled into both eyes, one drop 1...3 times, every 15 minutes.
Migrena se caracterizează prin atacuri recurente de cefalee severă, pulsatilă, de obicei unilaterală, agravată de mişcare, cu durata de 4…72 ore, asociată de disfuncţie autonomă (greaţă, vomă), foto- şi/sau fonofobie, precedată sau însoţită la unii pacienţi de fenomene neurologice focale tranzitorii (aură) (Stovner L., Zwart J., Hagen K., et al. Epidemiology of headache in Europe. European Journal of Neurology. 2006, 13, p. 333-345). Migraine is characterized by recurrent attacks of severe, pulsating headache, usually unilateral, aggravated by movement, lasting 4…72 hours, associated with autonomic dysfunction (nausea, vomiting), photo- and/or phonophobia, preceded or accompanied in some patients by transient focal neurological phenomena (aura) (Stovner L., Zwart J., Hagen K., et al. Epidemiology of headache in Europe. European Journal of Neurology. 2006, 13, p. 333-345).
Avantajele metodei constau în comoditatea de administrare a beta-blocantului sub formă de colir oftalmic în perioada de prodrom al crizei migrenoase, ce stopează accesul migrenos sau reduce intensitatea cefaleei. Metoda este foarte comodă, ieftină, cu efect rapid şi accesibilă pentru pacienţi. Probabilitatea reacţiilor adverse ale medicamentului este cu mult mai mică. The advantages of the method consist in the convenience of administering the beta-blocker in the form of eye drops during the prodrome of the migraine attack, which stops the migraine attack or reduces the intensity of the headache. The method is very convenient, cheap, with a quick effect and accessible to patients. The probability of adverse reactions of the drug is much lower.
Metoda constă în aceea că la apariţia primelor semne ale atacului migrenos se picură în ambii ochi picături oftalmice de 0,5% de timolol sau de 0,25% de betaxolol, câte o picătură de 1…3 ori, peste fiecare 15 min. Aceste semne de prodrom pacientul le cunoaşte din experienţa proprie a debutului crizelor migrenoase. The method consists in that at the first signs of a migraine attack, eye drops of 0.5% timolol or 0.25% betaxolol are instilled into both eyes, one drop 1...3 times, every 15 minutes. The patient knows these prodromal signs from his own experience of the onset of migraine attacks.
Exemplul 1 Example 1
Pacienta A., 33 ani. Diagnosticul: migrenă episodică rară, catamenială, cu aură vizuală sub formă de fosfene şi scotoame intermitente. În perioada de 3 luni din 4 atacuri migrenoase au fost stopate 3, instilând câte o picătură de soluţie de timolol de 0,5% în ambii ochi, peste fiecare 15 min, de 2 ori în timpul aurei migrenoase. În atacul necupat, intensitatea cefaleei a scăzut de la 8 puncte până la 2…3 puncte (după Scala Analogică Vizuală). Pacientul este consultat în fiecare lună şi continuă tratamentul la necesitate. Patient A., 33 years old. Diagnosis: rare episodic, catamenial migraine, with visual aura in the form of phosphenes and intermittent scotomas. During the 3-month period, 3 out of 4 migraine attacks were stopped by instilling one drop of 0.5% timolol solution in both eyes, every 15 minutes, 2 times during the migraine aura. In the non-stop attack, the headache intensity decreased from 8 points to 2…3 points (according to the Visual Analogue Scale). The patient is consulted every month and continues treatment if necessary.
Exemplul 2 Example 2
Pacientul B., 26 ani. Diagnosticul: migrenă episodică rară, cu aură vizuală sub formă de vedere mozaică, scotoame intermitente. Din 8 atacuri desfăşurate în perioada studiului, 6 au fost stopate instilând câte o picătură de soluţie de timolol de 0,5% în ambii ochi doar o singură dată, în celelalte 2 atacuri a scăzut intensitatea cefaleei de la 7 puncte până la 2 puncte, administrând peste fiecare 15 min de 3 ori în timpul aurei migrenoase. Patient B., 26 years old. Diagnosis: rare episodic migraine, with visual aura in the form of mosaic vision, intermittent scotomas. Out of 8 attacks during the study period, 6 were stopped by instilling one drop of 0.5% timolol solution in both eyes only once, in the other 2 attacks the headache intensity decreased from 7 points to 2 points, administered every 15 minutes 3 times during the migraine aura.
Pacientul este consultat peste fiecare 3 luni şi continuă tratamentul la necesitate. The patient is consulted every 3 months and continues treatment if necessary.
Metoda dată a fost aplicată la 17 pacienţi din cadrul catedrelor de oftalmologie şi neurologie ale USMF şi Institutului de Neurologie şi Neurochirurgie cu o eficacitate bună. This method was applied to 17 patients from the departments of ophthalmology and neurology of the University of Medical Sciences and the Institute of Neurology and Neurosurgery with good efficacy.
1. Etemadifar M., Abedi M. The preventive Role of Topical Timolol in Treatment of Migraine Headaches. Journal of Research in Medical Sciences. 2005, 10, p. 288-291 1. Etemadifar M., Abedi M. The preventive role of topical timolol in the treatment of migraine headaches. Journal of Research in Medical Sciences. 2005, 10, p. 288-291
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20150138A MD1018Z (en) | 2015-10-01 | 2015-10-01 | Method for treating migraine attack in patients with episodic migraine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20150138A MD1018Z (en) | 2015-10-01 | 2015-10-01 | Method for treating migraine attack in patients with episodic migraine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1018Y MD1018Y (en) | 2016-03-31 |
| MD1018Z true MD1018Z (en) | 2016-10-31 |
Family
ID=55646057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20150138A MD1018Z (en) | 2015-10-01 | 2015-10-01 | Method for treating migraine attack in patients with episodic migraine |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1018Z (en) |
-
2015
- 2015-10-01 MD MDS20150138A patent/MD1018Z/en not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| Etemadifar M., Abedi M. The preventive Role of Topical Timolol in Treatment of Migraine Headaches. Journal of Research in Medical Sciences. 2005, 10, p. 288-291 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD1018Y (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy | |
| US20110052678A1 (en) | Method for treating age related macular degeneration | |
| ES2709180T3 (en) | Brimonidine and timolol solutions without preservatives | |
| US20110021974A1 (en) | Retinitis pigmentosa treatment and prophalaxis | |
| Ferris | Results of 20 years of research on the treatment of diabetic retinopathy | |
| RU2013125146A (en) | FOLIC ACID AND RAMIPRIL COMBINATION: CYTO-PROTECTIVE, NEURO-PROTECTIVE AND RETIN-PROTECTIVE OPHTHALMOLOGICAL COMPOSITIONS | |
| WO2005030221A1 (en) | Therapeutic agent for ageing macular degeneration | |
| RU2006124557A (en) | COMPOSITIONS AND METHODS FOR INTRODUCING TUBULIN BINDING MEDICINES FOR TREATMENT OF EYE DISEASES | |
| ES2964629T3 (en) | Eye drops with citric acid as the only active ingredient | |
| JP2015523986A5 (en) | ||
| RU2134107C1 (en) | Preparation "gistokhrom" for treatment of eye retina and cornea inflammatory sicknesses | |
| US20200188405A1 (en) | Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma | |
| HRP20210418T1 (en) | TREATMENT WITH SYD985 PATIENTS WITH CANCER NOT RESPONDING TO T-DM1 | |
| JP2009519962A5 (en) | ||
| Wu et al. | Ocular and Orbital Complications of Intraarterial Cisplatin A Case Report | |
| MD1018Z (en) | Method for treating migraine attack in patients with episodic migraine | |
| RU2012120096A (en) | OPHTHALMIC DRUGS BASED ON BDNF (NEUROTROPHIC BRAIN FACTOR) AND THEIR APPLICATION | |
| RU2582284C1 (en) | Ophthalmic gel composition for treating conjunctivitis, blepharitis, keratitis corneal erosion associated with inflammatory eye diseases of non-infectious or post-infectious etiology and allergic lesions of ocular surface | |
| ES2356244T3 (en) | PREPARATION OF FLUPIRTINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OF THE VISUAL SYSTEM AND DIATEBES MELLITUS. | |
| RU2513473C1 (en) | Method of treating retinal and vitreous hemorrhage | |
| CN1049602C (en) | Compound injection for curing ischemic eye disease | |
| RU2345740C1 (en) | Method of dystrophic eye diseases treatment by means of medicinal mud remedy "relict-05" | |
| TW201028176A (en) | Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye | |
| WO2025132723A1 (en) | Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory damages of the visual pathway | |
| Misiuk-Hojło et al. | The issue of preservatives in light of evidence based medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) |